2-23 CAR T cells

2-23 CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy targeting C-type lectin-like molecule 1 (CLL-1, also known as CLEC12A). Developed by researchers at Osaka University, these CAR T cells utilize a novel, high-affinity monoclonal antibody clone (2-23) that demonstrates superior binding affinity and sensitivity compared to the widely used M26 clone. The therapy is designed to treat acute myeloid leukemia (AML), including cases with low CLL-1 expression. The CAR construct incorporates CD28 costimulatory and CD3ζ activation domains. Preclinical studies indicate that 2-23 CAR T cells exhibit potent cytotoxicity and cytokine production against AML cells and can be sensitized by menin inhibitors like revumenib, which upregulate CLL-1 expression in certain AML subtypes harboring MLL fusion genes or NPM1 mutations.

Other names

anti-CLL-1 CAR T cells (clone 2-23)CLL-1 CAR T cellsCLL1 CAR T cellsCLL 1 CAR T cells